Opinion: Proposed HHS rule on gender-affirming care radic...
If this rule is enacted, “any kind of care could be subject to similar treatment,” the experts write.
What’s Happening
So basically If this rule is enacted, “any kind of care could be subject to similar treatment,” the experts write.
First Opinion First Opinion What giving flu shots backstage taught me about public health By Ram Koppaka First Opinion First Opinion STAT Plus: China biotech’s Cambrian explosion By Brian Finrow First Opinion First Opinion 4 questions to understand the costs of ‘medical freedom’ By Sarah Despres First Opinion First Opinion Researchers have a moral obligation to push back when their studies are twisted to promote false health claims By John Gregory Neurotransmissions Neurotransmissions STAT Plus: What Ozempic might tell us about the future of Alzheimer’s By Jason Karlawish STAT Plus: FDA voucher program has become vehicle for political interference in drug review decisions, staffers say By Lizzy Lawrence STAT Plus: I’m the former head of Pfizer R&D. I’m worried about biopharma’s future By John L. (we’re not making this up)
LaMattina STAT Plus: The Worst Biopharma CEO of 2025 made decisions with tragic consequences By Adam Feuerstein STAT Plus: Data on Humana’s clinics looked dismal.
Why This Matters
Then its corporate research machine got to work By Casey Ross and Tara Bannow STAT Plus: RFK Jr.
Medical professionals are taking note of this development.
The Bottom Line
This story is still developing, and we’ll keep you updated as more info drops.
How do you feel about this development?
Daily briefing
Get the next useful briefing
If this story was worth your time, the next one should be too. Get the daily briefing in one clean email.
Reader reaction
